The funding round, which is reportedly at a $1.5 billion pre-money valuation, is led by Sequoia Capital. 23andMe will likely use the funds to expand its genetics research arm, according to TechCrunch. Although the Food and Drug Administration ordered the company to cease sales of its genomics tests in 2013, the agency began approving its updated products for select diseases in 2015.
23andMe and Sequoia declined TechCrunch‘s request for comment.
More articles on data analytics & precision medicine:
Kalorama: Apple, Google, IBM make waves in healthcare analytics market
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant
University of Rochester Medical Center taps NextGate to aggregate provider data
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
